Literature DB >> 18037881

MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling.

Rehan Ahmad1, Deepak Raina, Vishal Trivedi, Jian Ren, Hasan Rajabi, Surender Kharbanda, Donald Kufe.   

Abstract

Nuclear factor-kappaB (NF-kappaB) is constitutively activated in diverse human malignancies by mechanisms that are not understood. The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas and, similarly to NF-kappaB, blocks apoptosis and induces transformation. This study demonstrates that overexpression of MUC1 in human carcinoma cells is associated with constitutive activation of NF-kappaB p65. We show that MUC1 interacts with the high-molecular-weight IkappaB kinase (IKK) complex in vivo and that the MUC1 cytoplasmic domain binds directly to IKKbeta and IKKgamma. Interaction of MUC1 with both IKKbeta and IKKgamma is necessary for IKKbeta activation, resulting in phosphorylation and degradation of IkappaBalpha. Studies in non-malignant epithelial cells show that MUC1 is recruited to the TNF-R1 complex and interacts with IKKbeta-IKKgamma in response to TNFalpha stimulation. TNFalpha-induced recruitment of MUC1 is dependent on TRADD and TRAF2, but not the death-domain kinase RIP1. In addition, MUC1-mediated activation of IKKbeta is dependent on TAK1 and TAB2. These findings indicate that MUC1 is important for physiological activation of IKKbeta and that overexpression of MUC1, as found in human cancers, confers sustained induction of the IKKbeta-NF-kappaB p65 pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037881      PMCID: PMC4209910          DOI: 10.1038/ncb1661

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  35 in total

1.  The epidermal growth factor receptor is not required for tumor necrosis factor-alpha action in normal mammary epithelial cells.

Authors:  L M Varela; K M Darcy; M M Ip
Journal:  Endocrinology       Date:  1997-09       Impact factor: 4.736

2.  Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis.

Authors:  D M Brantley; F E Yull; R S Muraoka; D J Hicks; C M Cook; L D Kerr
Journal:  Mech Dev       Date:  2000-10       Impact factor: 1.882

Review 3.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 4.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

5.  Tumor necrosis factor-alpha: a multifunctional regulator of mammary gland development.

Authors:  L M Varela; M M Ip
Journal:  Endocrinology       Date:  1996-11       Impact factor: 4.736

6.  TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation.

Authors:  Marzenna Blonska; Prashant B Shambharkar; Masayuki Kobayashi; Dongyu Zhang; Hiroaki Sakurai; Bing Su; Xin Lin
Journal:  J Biol Chem       Date:  2005-10-31       Impact factor: 5.157

7.  MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets.

Authors:  V G Dyomin; N Palanisamy; K O Lloyd; K Dyomina; S C Jhanwar; J Houldsworth; R S Chaganti
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

8.  The death domain kinase RIP mediates the TNF-induced NF-kappaB signal.

Authors:  M A Kelliher; S Grimm; Y Ishida; F Kuo; B Z Stanger; P Leder
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

9.  TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway.

Authors:  Giichi Takaesu; Rama M Surabhi; Kyu-Jin Park; Jun Ninomiya-Tsuji; Kunihiro Matsumoto; Richard B Gaynor
Journal:  J Mol Biol       Date:  2003-02-07       Impact factor: 5.469

10.  Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.

Authors:  Yongqing Li; Derek Liu; Dongshu Chen; Surender Kharbanda; Donald Kufe
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

View more
  111 in total

1.  MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.

Authors:  Maroof Alam; Rehan Ahmad; Hasan Rajabi; Donald Kufe
Journal:  Mol Cancer Res       Date:  2014-11-03       Impact factor: 5.852

2.  Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Authors:  Geou-Yarh Liou; Heike Döppler; Brian Necela; Brandy Edenfield; Lizhi Zhang; David W Dawson; Peter Storz
Journal:  Cancer Discov       Date:  2014-10-31       Impact factor: 39.397

Review 3.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

Review 4.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

Review 5.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

6.  MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation.

Authors:  Lei Huang; Xiaodong Liao; Michael Beckett; Yuan Li; Kum Kum Khanna; Zhugang Wang; Surender Kharbanda; Ralph Weichselbaum; Donald Kufe
Journal:  Genes Cancer       Date:  2010-03

7.  MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR.

Authors:  Hasan Rajabi; Caining Jin; Rehan Ahmad; Cain McClary; Maya Datt Joshi; Donald Kufe
Journal:  Genes Cancer       Date:  2010-01-01

Review 8.  Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development.

Authors:  Juan Wang; Guixiang Tai
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

9.  The contribution of cell phenotype to the behavior of gastric cancer.

Authors:  Enrico Solcia; Catherine Klersy; Alessandro Vanoli; Federica Grillo; Rachele Manca; Francesca Tava; Ombretta Luinetti; Roberto Fiocca
Journal:  Gastric Cancer       Date:  2013-01-18       Impact factor: 7.370

10.  Anti-inflammatory effect of MUC1 during respiratory syncytial virus infection of lung epithelial cells in vitro.

Authors:  Yusheng Li; Darrell L Dinwiddie; Kevin S Harrod; Yong Jiang; K Chul Kim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-01-15       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.